ArticleGynecologic oncology reports2025
Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: As the use of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique condition are needed. Methods: In this case report, we demonstrate the case of a patient with advanced ovarian cancer and a pathogenic BRCA1 mutation who developed MDS following 4 years of maintenance PARPi. Results: Management of therapy-related MDS/AML is variable. In addition, subsequent oncologic treatments may be limited due to risk of MDS/AML recurrence with exposure to cytotoxic therapies and/or PARPi. Risk for MDS/AML recurrence can be monitored and predicted by evaluation for clonal hematopoiesis. This patient underwent autologous stem cell transplant. After subsequent disease recurrence, she underwent repeat germline testing which showed BRCA1 wildtype. In addition, no clonal hematopoietic clones were identified using a specialized institutional assay. For this reason and given previous durable response to PARPi, the patient was re-treated with a PARPi. Conclusions: This case highlights the unique management of therapy-related MDS/AML and underscores the importance of multidisciplinary care in determining safety of subsequent cancer-directed therapies in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.